Letters eGFR and chronic kidney disease

Time to move forward

BMJ 2007; 335 doi: https://doi.org/10.1136/bmj.39273.574479.BE (Published 19 July 2007) Cite this as: BMJ 2007;335:111
  1. C R V Tomson, past chair, Joint Specialty Committee on Renal Medicine of the Renal Association and the Royal College of Physicians1,
  2. E J Lamb, consultant clinical scientist2,
  3. K Griffith, general practitioner3,
  4. D O'Donoghue, national clinical director of kidney care4,
  5. J Feehally, immediate past president, Renal Association5
  1. 1Renal Medicine, Southmead Hospital, Bristol BS10 5NB
  2. 2Clinical Biochemistry, East Kent Hospitals NHS Trust, Kent and Canterbury Hospital, Canterbury CT1 3NG
  3. 3University Health Centre, York University, York YO10 5DD
  4. 4Department of Nephrology, Salford Royal Hospital NHS Trust, Hope Hospital, Salford M6 8HD
  5. 5John Walls Renal Unit, Leicester General Hospital, Leicester LE5 4 PW
  1. edmund.lamb{at}ekht.nhs.uk

    Giles and Fitzmaurice's arguments are designed to persuade BMJ readers that reporting estimated glomerular filtration rate (eGFR) has introduced a screening programme by the back door, will pressurise specialist services, and cause unnecessary anxiety and harm to patients in terms of getting life insurance and receiving inappropriate treatment.1

    The marked increase in referrals of patients with …

    View Full Text

    Sign in

    Log in through your institution